BioXcel TherapeuticsBTAI
About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Employees: 74
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
18.74% less ownership
Funds ownership: 26.35% [Q2] → 7.62% (-18.74%) [Q3]
32% less funds holding
Funds holding: 73 [Q2] → 50 (-23) [Q3]
35% less call options, than puts
Call options by funds: $22K | Put options by funds: $34K
74% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 27
79% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 29
85% less capital invested
Capital invested by funds: $12.6M [Q2] → $1.89M (-$10.8M) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 111 / 295 met price target | 730%upside $5 | Buy Maintained | 21 Oct 2024 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 111 / 295 met price target | 1,061%upside $7 | Buy Reiterated | 6 Sept 2024 |
Canaccord Genuity Sumant Kulkarni 42% 1-year accuracy 10 / 24 met price target | 1,061%upside $7 | Buy Maintained | 30 Aug 2024 |
Financial journalist opinion
Based on 5 articles about BTAI published over the past 30 days
